Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
- Conditions
- Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Thoracic Esophagus AdenocarcinomaCervical Esophagus AdenocarcinomaGastroesophageal Junction AdenocarcinomaPathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04615013
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 10
- Registration Number
- NCT04608786
- Locations
- 🇨🇳
Renji Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai, China
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 816
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars- Sinai Medical Center, Los Angeles, California, United States
🇺🇸Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 1332
- Registration Number
- NCT04595565
- Locations
- 🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
🇪🇸Hospital Galdakao-Usansolo, Galdakao, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Spain
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 204
- Registration Number
- NCT04571437
- Locations
- 🇪🇬
Faculty of Medicine, Cairo University, Cairo, Egypt
ONO-4538 Phase II Rollover Study (ONO-4538-98)
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 59
- Registration Number
- NCT04566380
- Locations
- 🇯🇵
Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan
🇯🇵Tokyo Clinical Site3, Bunkyo-ku, Tokyo, Japan
🇯🇵Chiba Clinical Site2, Chiba, Japan
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 48
- Registration Number
- NCT04564898
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, Italy
🇮🇹Azienda Ospedaliero Universitaria Pisana, Pisa, PI, Italy
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT04556773
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT04539808
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 49
- Registration Number
- NCT04534218
- Locations
- 🇫🇷
Hôpital Nord Franche-Comté, Montbéliard, France
🇫🇷CHU de Besançon, Besançon, France
🇫🇷Centre georges-François Leclerc, Dijon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.